A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part open-label extension (OLE) period with a duration of approximately 32 weeks.

Start Date01 Feb 2025

Sponsor / Collaborator

Amylyx Pharmaceuticals, Inc.

NCT04652479

/ CompletedPhase 2IIT

A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia

The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.

Start Date21 Jun 2021

Sponsor / Collaborator

Eiger BioPharmaceuticals, Inc.

ACTRN12619000791134

/ SuspendedPhase 1

A pilot trial of Exendin PET scanning in metastatic castrate resistant prostate cancer to demonstrate GLP1 receptor positive disease

Start Date28 Jun 2019

Sponsor / Collaborator-

100 Clinical Results associated with Avexitide

100 Translational Medicine associated with Avexitide

100 Patents (Medical) associated with Avexitide

609

Literatures (Medical) associated with Avexitide

01 Mar 2025·MOLECULAR NUTRITION & FOOD RESEARCH

Ashitaba Chalcone 4‐Hydroxydericcin Promotes Glucagon‐Like Peptide‐1 Secretion and Prevents Postprandial Hyperglycemia in Mice

Article

Author: Abe, Ayane ; Odongo, Kevin ; Ishinaka, Moe ; Ashida, Hitoshi ; Harada, Naoki ; Yamaji, Ryoichi ; Yamashita, Yoko

ABSTRACT:

Certain polyphenols improve glucose tolerance by stimulating glucagon‐like peptide‐1 (GLP‐1) secretion from intestinal L‐cells. Ashitaba chalcones, 4‐hydroxyderricin (4‐HD), and xanthoangelol (XAG) have antihyperglycemic effects, but their molecular mechanism, including whether they promote GLP‐1 secretion is unknown. This study investigates the 4‐HD‐induced GLP‐1 secretory mechanisms and its anti‐hyperglycemic effects. The secretory mechanisms were examined in STC‐1 cells and antihyperglycemic effects in male ICR mice. In STC‐1 cells, 4‐HD, but not XAG, stimulated GLP‐1 secretion through membrane depolarization and intracellular Ca2+ increase [Ca2+]i, via the L‐type Ca2+ channel (VGCC). Verapamil and nifedipine, blockers of VGCC, and treatment in Ca2+‐free buffer abolished 4‐HD effects on [Ca2+]i and GLP‐1 secretion. Moreover, 4‐HD activated CaMKII and ERK1/2. Consistently, oral 4‐HD suppressed postprandial hyperglycemia in mice and increased plasma GLP‐1 and insulin levels, GLUT4 translocation, and activation of LKB‐1 and Akt pathways in skeletal muscle. Furthermore, exendin 9–39, a GLP‐1R antagonist, and compound C, an AMPK inhibitor, completely canceled the 4‐HD‐caused anti‐hyperglycemic activities.4‐HD stimulated GLP‐1 secretion through membrane depolarization coupled with [Ca2+]i increase via VGCC in L‐cells and activated AMPK‐ and insulin‐induced GLUT4 translocation in skeletal muscle. Thus, 4‐HD possesses dual mechanisms for the prevention of hyperglycemia.

01 Jan 2025·METABOLISM-CLINICAL AND EXPERIMENTAL

Fam3a-mediated prohormone convertase switch in α-cells regulates pancreatic GLP-1 production in an Nr4a2-Foxa2-dependent manner

Article

Author: Lin, Xiafang ; Li, Jian ; Wang, Dandan ; Xia, Li ; Wei, Rui ; Lang, Shan ; Wei, Tianjiao ; Le, Yunyi ; Yin, Deshan ; Liao, Xinyue ; Wu, Qi ; Yang, Jin ; Yang, Jichun ; Hong, Tianpei ; Cui, Xiaona ; Li, Fei ; Jiang, Yafei

BACKGROUND:

Fam3a has been demonstrated to regulate pancreatic β-cell function and glucose homeostasis. However, the role and mechanism of Fam3a in regulating α-cell function remain unexplored.

METHODS:

Glucagon and glucagon-like peptide-1 (GLP-1) levels in pancreas and plasma were measured in global Fam3a knockout (Fam3a^-/-) mice. Human islet single-cell RNA sequencing (scRNA-seq) datasets were utilized to analyze gene expression correlations between FAM3A and PCSK1 (encoding PC1/3, which processes proglucagon into GLP-1). Mouse pancreatic α-cell line αTC1.9 cells were transfected with Fam3a siRNA or plasmid for Fam3a knockdown or overexpression to explore the effects of Fam3a on PC1/3 expression and GLP-1 production. The downstream mediator (including Nr4a2) was identified by transcriptomic analysis, and its role was confirmed by Fam3a knockdown or overexpression in αTC1.9 cells. Based on the interacted protein of Nr4a2 and the direct binding to Pcsk1 promoter, the transcription factor Foxa2 was selected for further verification. Nuclear translocation assay and dual-luciferase reporter assay were used to clarify the involvement of Fam3a-Nr4a2-Foxa2 pathway in PC1/3 expression and GLP-1 production. Moreover, α-cell-specific Fam3a knockout (Fam3a^α-/-) mice were constructed to evaluate the metabolic variables and hormone levels under normoglycemic, high-fat diet (HFD)-fed and streptozotocin (STZ)-induced diabetic conditions. Exendin 9-39 (Ex9), a GLP-1 receptor antagonist, was used to investigate GLP-1 paracrine effects in Fam3a^α-/- mice and in their primary islets.

RESULTS:

Compared with wild-type mice, pancreatic and plasma active GLP-1 levels were increased in Fam3a^-/- mice. Analysis of human islet scRNA-seq datasets showed a significant negative correction between FAM3A and PCSK1 in α-cells. Fam3a knockdown upregulated PC1/3 expression and GLP-1 production in αTC1.9 cells, while Fam3a overexpression displayed inverse effects. Transcriptomic analysis identified Nr4a2 as a key downstream mediator of Fam3a, and Nr4a2 expression in αTC1.9 cells was downregulated and upregulated by Fam3a knockdown and overexpression, respectively. Nr4a2 silencing increased PC1/3 expression, albeit Nr4a2 did not directly bind to Pcsk1 promoter. Instead, Nr4a2 formed a complex with Foxa2 to facilitate Fam3a-mediated Foxa2 nuclear translocation. Foxa2 negatively regulated PC1/3 expression and GLP-1 production. Besides, Foxa2 inhibited the transcriptional activity of Pcsk1 promoter at specific binding sites 10 and 6, and this inhibition was intensified by Nr4a2 in αTC1.9 cells. Compared with Flox/cre littermates, improved glucose tolerance, increased active GLP-1 level in pancreas and plasma, upregulated plasma insulin level in response to glucose, and decreased plasma glucagon level were observed in Fam3a^α-/- mice. Primary islets isolated from Fam3a^α-/- mice also showed an increase in active GLP-1 and insulin release. In addition, the insulinotropic effect of intra-islet GLP-1 was blocked by Ex9 in Fam3a^α-/- mice and in their primary islets. Similarly, HFD-fed Fam3a^α-/- mice also exhibited an improved glucose tolerance. Both HFD-fed and STZ-induced diabetic Fam3a^α-/- mice showed an increased pancreatic active GLP-1 level, an elevated plasma insulin level and a reduced plasma glucagon level.

CONCLUSIONS:

Fam3a deficiency in α-cells enhances pancreatic GLP-1 production to improve β-cell function via paracrine signaling in an Nr4a2-Foxa2-PC1/3-dependent manner. Our study unveils a novel strategy for reprogramming α-cell proglucagon processing output from glucagon to GLP-1 and deepen the understanding of crosstalk between α-cells and β-cells.

01 Jan 2025·Obesity

GLP‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it

Article

Author: DeFronzo, Ralph ; Carli, Fabrizia ; Gastaldelli, Amalia ; Rayas, Maria ; Pezzica, Samantha ; Salehi, Marzieh ; Peterson, Richard ; Honka, Henri

Abstract:

Objective:

The glycemic‐independent actions of glucagon‐like peptide‐1 (GLP‐1) in the prandial state in humans are unknown. We examined the contribution of GLP‐1 to β‐cell secretory response (primary endpoint) and glucose metabolism during protein ingestion under basal glycemia, as well as whether these responses are affected by rerouted gut after gastric bypass (GB) or sleeve gastrectomy (SG).

Methods:

Insulin secretion rate (ISR) and glucose fluxes during a 50‐g oral protein load were compared among 10 nondiabetic individuals with GB, 9 with SG, and 7 non‐operated controls (CN), with and without intravenous infusion of exendin(9‐39) (Ex‐9), a GLP‐1 receptor (GLP‐1R) antagonist.

Results:

Blocking GLP‐1R increased glucose before and after protein ingestion and decreased β‐cell sensitivity to glucose in the first 30 min of protein ingestion in all three groups (p < 0.05). Reduction in the premeal ISR by Ex‐9 infusion was only observed in CN, whereas diminished prandial ISR3h by GLP‐1R blockade was only observed in GB and SG (p < 0.05 for interaction). GLP‐1R blockade enhanced post‐protein insulin action in GB and SG, but not in CN, and exaggerated endogenous glucose production only GB (p < 0.05 for interaction).

Conclusions:

These findings are consistent with both pancreatic and extra‐pancreatic roles for GLP‐1 during protein ingestion in humans that are exaggerated by bariatric surgery.image

News (Medical) associated with Avexitide

19 Feb 2025

·www.biospace.com

Biopharma Bankruptcies Still At Peak, With Little Relief in Sight

iStock, Yutthana Gaetgeaw 2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024. Biopharma bankruptcies are still at higher-than-normal levels, with 2024 seeing 13 firms go under in this way—just one less than the industry’s 10-year high of 14 in 2023—underscoring the perilous fundraising situation that has persisted since the pandemic bubble burst. “Chapter 11 is really just the tip of the iceberg,” Cristine Schwarzman, a partner in Ropes & Gray’s business restructuring practice, told BioSpace in an email. While the bankruptcy code is the most commonly reported way that companies shut down, it’s not the only way. “Many more biotechs go through ABC proceedings and just dissolve, because those processes are less expensive and quicker, even though they do not provide the same benefits as the ‘free and clear’ provisions of the bankruptcy code,” Schwarzman said. Prior to 2023, the highest number of biopharma bankruptcies since 2010 came in 2019 when seven companies filed for Chapter 11 protection. David McIntosh, also a partner at Ropes & Gray in the life sciences and intellectual property transactions practice, said the key driver of this recent peak is fundraising challenges, particularly as interest rates have risen and strained access to capital. There has also been economic uncertainty due to the political environment, leading to more restrained investing, McIntosh explained. “The public markets have been cool for biotech companies, and private investors, like VCs, are being more selective in which (and how many) companies they are willing to invest in,” he told BioSpace . in an email. Meanwhile, Big Pharma has not been as quick to deal as analysts and investors had hoped, and the larger companies have also cut back on R&D expenditures. This challenging funding environment follows the pandemic boom, which saw an influx of funds across the life sciences. “The ease with which companies were able to raise capital during the pandemic resulted in biotech companies taking on more debt financing than previously in the life sciences industry,” Schwarzman said. Because of the high rate of debt financings, more companies had to go through the bankruptcy process to “de-lever” their balance sheets, she added. “I think it is also safe to say that during the pandemic, a number of private biotech companies went public that might not have been able to in normal market times,” McIntosh said. These public companies are more likely to seek bankruptcy protection because they typically have a higher valuation, more complex capital structure and investors with access to capital to fund the Chapter 11 process, Schwarzman said. Smaller private companies, on the other hand, tend to be able to wrap things up through state court processes. “To be clear, however, both private and public biotech companies are facing financial pressure right now,” Schwarzman added. Unfortunately, Schwarzman and McIntosh see the trend continuing this year. Due to geopolitical uncertainty “and the increasing likelihood that interest rates will at a minimum not be cut to deal with the continuing inflationary environment,” McIntosh said, “we do not expect these trends to fall off.” Beginning of the End To McIntosh, the most surprising bankruptcy of 2024 was Eiger BioPharmaceuticals, a metabolic disease biotech that was advancing peginterferon lambda for chronic hepatitis delta until a liver safety signal arose in a Phase III trial. “It had raised a lot of money and had a lot of interesting assets, but experienced a Phase III failure in 2023, which seemed to be the beginning of the end,” McIntosh said. Eiger sold off its assets, with some landing at Amylyx Pharmaceuticals for future development. Amylyx paid $35 million for the glucagon-like peptide-1 receptor antagonist avexitide, which is expected to begin a Phase III trial this quarter . This is a fairly typical path for the assets left behind in a biotech bankruptcy, McIntosh explained. The intellectual property is sold to other companies, presenting the new owner with the opportunity to use the assets to attract new financing at a lower valuation, he said; it also gives the drugs a second chance. Another major bankruptcy of 2024 was Gritstone bio, which filed in October in an effort to save its R&D operations. The vaccines-focused biotech was pursuing a stalking horse transaction, when a party swoops in to buy out a bankrupt company’s assets prior to a court auction process. Ultimately, Gritstone’s assets were auctioned off for $21.2 million, according to a Jan. 3 filing. Gritstone was optimistic about Phase II results for its Granite program in September 2024, which showed a 21% relative risk reduction of progression or death in patients taking the study medication versus standard of care. But the data needed more time to mature and Gritstone was running out of runway, with just $61.7 million on hand, leading to the bankruptcy filing. Cell therapy biotech Athersys was another company to file, going the stalking horse route and selling its assets to Healios for around $2 million in January 2024. Athersys had been developing its MultiStem off-the-shelf cell therapy since 1994 in ischemic stroke in partnership with Healios. Other indications included traumatic injury and acute respiratory distress syndrome. A Phase III trial in stroke that read out in October 2023 was unsuccessful . This year, the bankruptcies have already started. According to a Jan. 29 SEC filing , Flagship Pioneering spinout Omega Therapeutics had until Feb. 10 to commence bankruptcy proceedings and begin to wind down operations, likely involving a sale process with Pioneering Medicines, an affiliate of Flagship Pioneering. The news came just over a year after Omega struck an obesity deal with Novo Nordisk. “As long as the public markets disfavor biotech companies, and private investors shy away from ‘riskier’ early-stage investments,” McIntosh said, “the trend will continue.” A note about the data: BioSpace ’s last bankruptcy analysis clocked 28 bankruptcies for 2023 as of October of that year. Our new analysis uses narrower criteria, including only companies making therapeutics. Our source for bankruptcies also shifted to S&P Capital IQ and company SEC filings.

Phase 3Clinical ResultCell TherapyPhase 2

04 Dec 2024

·www.businesswire.com

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria to the previous Phase 2 trials of avexitide in PBH. Amylyx expects that the first study participant will be dosed in the first quarter of 2025, followed by expected completion of recruitment in 2025, and anticipates topline data in 2026. “We are excited to advance avexitide into a Phase 3 clinical trial, marking a pivotal step toward bringing this investigational therapy to people living with PBH,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “The consistent data from five clinical trials of avexitide in PBH underscore avexitide’s potential to be the first therapy approved for people living with PBH.” LUCIDITY will be a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Approximately 75 participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial will include a three-week run-in period and a 16-week double-blind treatment period. Participants who complete the double-blind period of the planned study will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the reduction in the composite of Level 2 and Level 3 hypoglycemia events through Week 16. Safety and tolerability will also be evaluated. “PBH is believed to result from an excessive GLP-1 response leading to persistent, recurrent, and debilitating hypoglycemia events that take a profound toll on someone’s quality of life. Avexitide is designed to bind to the GLP-1 receptor and inhibit the effects of excessive GLP-1 in PBH, mitigating hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. We are excited to evaluate avexitide, which has FDA Breakthrough Therapy and Orphan Drug Designations, in the Phase 3 LUCIDITY trial, following two Phase 2 clinical studies that demonstrated compelling clinical data supporting avexitide’s ability to significantly reduce the rates of hypoglycemia events,” said Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx. “Our goal in Phase 3 is to align the trial design as closely as possible with the prior studies. Importantly, we believe LUCIDITY is well powered to detect a treatment effect. We look forward to continuing to collaborate with study investigators and the PBH community as we seek to initiate LUCIDITY and advance avexitide through the clinical development process.” LUCIDITY was informed by data from five clinical trials of avexitide in people with PBH showing consistent, dose-dependent effects across studies. The five clinical trials include a Phase 1 trial, a single ascending dose trial, a multiple ascending dose trial, and two Phase 2 trials: In the Phase 2 ( PREVENT ), 28-day, randomized, placebo-controlled crossover trial (N=18), results showed a significant reduction in rates of Level 2 and 3 hypoglycemia events in participants with PBH after RYGB surgery following treatment with 30 mg twice daily and 60 mg once daily of avexitide compared with placebo. PREVENT’s primary endpoint was met with statistical significance, showing both avexitide dosing regimens improved the lowest glucose level (nadir) after a meal as measured during formal mixed meal tolerance testing (MMTT). Mean plasma glucose nadir was increased by 21% (p=0.001) and 26% (p=0.0002) following avexitide 30 mg twice daily and 60 mg once daily dosing, respectively, compared to placebo. In the Phase 2b, 28-day, open-label, investigator-initiated, crossover trial (N=16), 90 mg once daily and 45 mg twice daily of avexitide met its primary endpoint and significantly reduced rates of hypoglycemia events in participants following RYGB surgery and other upper-gastrointestinal surgeries. Participants in the Phase 2b trial receiving 90 mg once daily of avexitide, the dose Amylyx plans to evaluate in LUCIDITY, saw a statistically significant 53% reduction in Level 2 hypoglycemia events (p=0.004) and a statistically significant 66% reduction in Level 3 hypoglycemia events (p=0.0003). Avexitide was generally well tolerated, with a favorable safety profile replicated across the clinical trials. Amylyx will present the trial design at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on December 12-14, 2024. Following the conclusion of the poster presentation on December 12, the poster will be made available on the “Publications” page of the Amylyx website . About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemia events. In two Phase 2 PBH trials, avexitide demonstrated highly statistically significant reductions in hypoglycemia events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Symptomatic post-bariatric hypoglycemia (PBH) is a condition that affects approximately 8% of people who have undergone bariatric surgery, or approximately 160,000 people, in the U.S. PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemia events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X . For investors, please visit investors.amylyx.com . Forward-Looking Statements Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential of avexitide as a treatment for PBH; expectations regarding the timing of initiation of a Phase 3 trial of avexitide in PBH and the timing of results from the trial; and expectations regarding the potential for the results of a Phase 3 trial to support approval of avexitide; the Company’s expectations regarding its financial performance; and expectations regarding the Company’s cash runway and longer-term strategy. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx’ program development activities; Amylyx’ ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx’ ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx’ operations, as well as the risks and uncertainties set forth in Amylyx’ United States Securities and Exchange Commission (SEC) filings, including Amylyx’ Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Phase 2Phase 3Clinical ResultOrphan DrugBreakthrough Therapy

07 Nov 2024

·www.businesswire.com

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the third quarter ended September 30, 2024. “ This quarter, we continued to advance our late-stage pipeline as part of our goal to bring new potential treatments to communities with high unmet needs. We recently reported positive topline data from our Phase 2 HELIOS clinical trial in people living with Wolfram syndrome that show AMX0035 resulted in meaningful improvements across multiple measures of disease progression as well as sustained improvement over time. We plan to engage with the FDA and other stakeholders to inform our Phase 3 program in Wolfram,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “ Additionally, we are on track to initiate a Phase 3 program for our lead asset avexitide in post-bariatric hypoglycemia in the first quarter of next year and remain on track to report interim data from our Phase 2b/3 ORION clinical trial of AMX0035 in progressive supranuclear palsy in mid-2025. With cash runway into 2026, we believe we are well positioned to deliver on these milestones as we continue our critical work in neurodegenerative diseases and endocrine conditions.” Third Quarter and Recent Updates: Announced positive topline data for all 12 participants in the Phase 2 HELIOS clinical trial, a single-site, single-arm, open-label trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with Wolfram syndrome. Wolfram syndrome is a rare, progressive, monogenic disease impacting approximately 3,000 people in the U.S. HELIOS showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the trial’s primary efficacy endpoint, in contrast to the expected decrease in pancreatic function with disease progression. Similar overall improvements or stabilization were observed across all secondary endpoints, including hemoglobin A1c (HbA1c), time in target glucose range assessed by continuous glucose monitoring (CGM), and visual acuity. The safety profile of AMX0035 in HELIOS was consistent with prior safety data. The Company is engaging with stakeholders and plans to meet with the U.S. Food and Drug Administration (FDA) to inform a Phase 3 program and expects to provide an update in 2025. Acquired avexitide, a Phase 3-ready glucagon-like peptide-1 (GLP-1) receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation in hyperinsulinemic hypoglycemia. Avexitide has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in three clinical trials for congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia. In previous Phase 2 and Phase 2b studies in PBH, avexitide showed statistically significant reductions in hypoglycemia events. FDA guidance for industry combined with initial FDA feedback specific to the planned pivotal Phase 3 program of avexitide for PBH suggest that reduction in hypoglycemia events could be an endpoint to support approval following positive results from a pivotal Phase 3 clinical trial. Announced publication of data showing encouraging effects of AMX0035 on cerebrospinal fluid (CSF) biomarkers of core Alzheimer’s disease (AD) pathology and neurodegeneration in the peer-reviewed medical journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions , a journal of the Alzheimer’s Association. The exploratory analyses on CSF biomarkers from participants with AD from the Phase 2 PEGASUS clinical trial suggest that treatment with AMX0035 resulted in consistent changes in AD and neurodegeneration CSF biomarkers in participants with a broad range of disease severity. Findings from the exploratory analysis provide preliminary evidence that AMX0035 engages multiple pathological pathways related to neurodegeneration, including tau. Presented the planned Phase 1 study design of AMX0114 in people living with amyotrophic lateral sclerosis (ALS) at the 2024 Northeast ALS Consortium Annual Meeting. The Phase 1 LUMINA clinical trial, a multicenter, randomized, placebo-controlled, multiple ascending dose trial, will evaluate the safety and biological activity of AMX0114 in approximately 48 people living with ALS. Four dose levels of AMX0114 or placebo are planned to be examined sequentially starting with 12.5 mg. Received clearance from Health Canada for the Company’s Clinical Trial Application for AMX0114 in people living with ALS. Amylyx plans to begin the LUMINA trial with a starting dose of 12.5 mg in Canada by the end of 2024 or in early 2025. The Company also submitted an Investigational New Drug application to the FDA for AMX0114. The FDA restricted dosing to an amount that is lower than the Company’s proposed starting dose of 12.5 mg and has requested additional information, which resulted in a clinical hold. Toxicology data from studies showed a greater than 10X safety margin at the starting dose of 12.5 mg based on the no observed adverse effect level (NOAEL) determined by independent toxicology firms. Amylyx is working to address FDA comments and believes the trial can be completed outside of the U.S. if needed. The Company expects early cohort data from LUMINA in 2025. Upcoming Expected Milestones: The Company plans to initiate the Phase 1 LUMINA clinical trial of AMX0114 in people living with ALS by the end of 2024 or in the beginning of 2025 in Canada. AMX0114 is an antisense oligonucleotide targeting inhibition of calpain-2, a well-established target in a number of neurological diseases and a protease known to cleave many substrates including neurofilament, tau, and TDP43 proteins. Amylyx expects early cohort data from LUMINA in 2025. Amylyx continues to expect initiation of its Phase 3 program for avexitide in PBH in the first quarter of 2025. Topline data are anticipated in 2026. Data from an interim analysis of the Phase 2b/3 ORION clinical trial of AMX0035 in progressive supranuclear palsy (PSP) continue to be expected in mid-2025. ORION is an operationally seamless Phase 2b/3 clinical trial. The Phase 2b portion will include approximately 100 people living with PSP. Amylyx plans to conduct an interim analysis in these participants through Week 24 and will use this data to inform a go/no-go decision on the Phase 3 portion of the trial in mid-2025. Financial Results for the Third Quarter Ended September 30, 2024 Net product revenue: Net product revenue was $0.4 million for the three months ended September 30, 2024 and was related to adjustments to the Company’s gross-to-net accrual estimates for prior period sales of RELYVRIO ® and ALBRIOZA™. As previously disclosed, on April 4, 2024, the Company announced that it had started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO and ALBRIOZA and remove the product from the market based on topline results from the global Phase 3 PHOENIX trial, which did not meet its prespecified primary and secondary endpoints. Cost of Sales: Cost of sales were $0.8 million in the three months ended September 30, 2024, and were related to estimated losses on firm commitments under commercial manufacturing supply agreements for AMX0035 that were established prior to the results from the Phase 3 PHOENIX trial. Acquired in-process research and development: Acquired in-process research and development expenses were $36.2 million for the three months ended September 30, 2024, compared to zero for the same period in 2023. The increase was due to the acquired in-process research and development assets of avexitide. R&D Expenses: Research and development expenses were $21.2 million for the three months ended September 30, 2024, compared to $30.0 million for the same period in 2023. The decrease was primarily due to a decrease in clinical expenses and a decrease in payroll and personnel-related costs. The decrease in clinical expenses is primarily due to a decrease in spending on AMX0035 for the treatment of ALS following the topline data from the PHOENIX trial. The decrease in payroll and personnel-related costs was primarily related to a decrease in the number of employees following the restructuring plan announced on April 4, 2024. SG&A Expenses: Selling, general and administrative expenses were $17.8 million for the three months ended September 30, 2024, compared to $48.7 million for the same period in 2023. The decrease was primarily due to a decrease in payroll and personnel-related costs and a decrease in consulting and professional services. The decrease in payroll and personnel-related costs was primarily related to a decrease in the number of employees as a result of the restructuring plan announced on April 4, 2024. The decrease in consulting and professional services was primarily due to a decrease in commercial sales and marketing activity as a result of removing RELYVRIO/ALBRIOZA from the markets in the U.S. and Canada based on topline results from the Phase 3 PHOENIX trial. Net Loss: Net loss for the three months ended September 30, 2024, was $72.7 million, or $1.07 per share, compared to net income of $20.9 million, or $0.30 per diluted share for the same period in 2023. Cash Position: Cash, cash equivalents, and marketable securities were $234.4 million as of September 30, 2024, compared to $309.8 million as of June 30, 2024. The Company expects cash runway into 2026. Investor Conference Call Information Amylyx’ management team will host a conference call today, November 7, 2024, at 8:00 a.m. ET to discuss financial results and provide an update on the business. To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events . The webcast will be archived and available for replay for 90 days following the event. Available Information We periodically provide other information for investors on our corporate website, https://amylyx.com , and our investor relations website, https://investors.amylyx.com . This includes press releases and other information about financial performance, information on corporate governance, and details related to our annual meeting of stockholders. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website, in addition to following the Company’s press releases, SEC filings, and public conference calls and webcasts. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 2 clinical studies for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), with U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for both indications and FDA Rare Pediatric Disease Designation in congenital HI. Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and block the effect of excessive GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent serious hypoglycemia events. In two Phase 2 PBH trials, avexitide demonstrated highly statistically significant reductions in hypoglycemia events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About AMX0035 AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the U.S.). AMX0035 was designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. We believe that our proprietary combination of PB and TURSO and their complementary mechanisms of action will allow us to synergistically target abnormal cell death to better prevent neurodegeneration than treatment targeted at either mechanism of action alone. AMX0035 is being studied as a potential treatment for Wolfram syndrome and progressive supranuclear palsy, two neurodegenerative diseases. About AMX0114 AMX0114 is an investigational antisense oligonucleotide designed to target the gene encoding calpain-2, a key contributor to the axonal (Wallerian) degeneration pathway. Axonal degeneration has been recognized as an important early contributor to the clinical presentation and pathogenesis of ALS and other neurodegenerative diseases. Calpain-2 has been implicated in the pathogenesis of ALS based on findings of elevated levels of calpain-2 and its cleavage products in postmortem ALS tissue, therapeutic benefit of calpain-2 modulation in animal models of ALS, and the role of calpain-2 in cleaving neurofilament, a broadly researched biomarker in ALS. Preclinical studies completed to date have shown that AMX0114 achieves potent, dose-dependent, and durable knockdown of CAPN2 mRNA expression and calpain-2 protein levels in human motor neurons. Moreover, in preclinical efficacy studies, treatment with AMX0114 reduced extracellular neurofilament light chain levels following neurotoxic insult in induced pluripotent stem cell (iPSC)-derived human motor neurons, and improved survival of iPSC-derived human motor neurons harboring ALS-linked, pathogenic TDP-43 mutations. About Post-Bariatric Hypoglycemia (PBH) Symptomatic post-bariatric hypoglycemia (PBH) is a condition that affects approximately 8% of people who have undergone bariatric surgery. It is characterized by an excessive glucagon-like peptide-1 (GLP-1) response, dysregulated secretion of insulin, and a rapid drop in blood sugar. PBH can cause serious hypoglycemia events associated with brain glucose starvation, known as neuroglycopenia, including impaired cognition, cardiac arrythmias, loss of consciousness, and seizures. PBH is associated with a high degree of disability and can result in major disruptions to life, including falls, motor vehicle accidents, and job and income loss. It is estimated that ~160,000 people are currently living with symptomatic PBH in the U.S., classifying it as an orphan condition. About Congenital Hyperinsulinism (HI) Congenital hyperinsulinism (HI) is a rare disease characterized by hypersecretion of insulin leading to severe, persistent hypoglycemia in infants and young children with limited therapeutic options. Common symptoms of congenital HI include lack of energy, irritability, lethargy, and excessive hunger. Repeated episodes of low blood glucose increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. About the HELIOS Trial HELIOS ( NCT05676034 ) is a 12-participant, single-site, single-arm, open-label, proof of biology, Phase 2 trial designed to study the effect of AMX0035 on safety and tolerability, and various measures of endocrinological, neurological, and ophthalmologic function in adult participants living with Wolfram syndrome. Participants in HELIOS receive AMX0035 for up to 96 weeks followed by a four-week safety follow-up. Primary and secondary outcomes are assessed at Week 24 and at longer-term time points. In September 2022, researchers from Washington University School of Medicine in St. Louis, including Dr. Urano, in collaboration with Amylyx, published preclinical data on AMX0035 in beta cell, neuronal cell, and mouse models of Wolfram syndrome in the peer-reviewed Journal of Clinical Investigation Insight . The FDA and the European Commission granted Orphan Drug Designation to AMX0035 for the treatment of Wolfram syndrome in November 2020 and August 2024, respectively. About Wolfram Syndrome Wolfram syndrome is a rare, monogenic neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy, and neurodegeneration. Common manifestations of Wolfram syndrome include diabetes mellitus and diabetes insipidus, gradual vision loss leading to blindness, hearing loss, neurogenic bladder, difficulties with balance and coordination, and difficulty breathing. Genetic and experimental evidence suggests that endoplasmic reticulum (ER) dysfunction is a critical pathogenic component of Wolfram syndrome. The prognosis of Wolfram syndrome is poor, and many people with the disease die prematurely with severe neurological disabilities. About the ORION Trial The ORION trial ( NCT06122662 ) is a global, randomized, double-blind, placebo-controlled Phase 2b/3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 compared to placebo in people living with progressive supranuclear palsy (PSP). ORION was designed and planned in collaboration with key global academic leaders, people living with PSP and their caregivers, and industry advocacy organizations. About PSP Progressive supranuclear palsy (PSP) is a sporadic, rare, and fatal neurodegenerative disorder that affects movement, gait, balance, eye movements, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis. PSP typically begins in late-middle age and rapidly progresses over time. The disease affects approximately seven in 100,000 people worldwide, and there are currently no disease-modifying therapies approved for the treatment of PSP. PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy. Similar to other neurodegenerative diseases, pathophysiologic changes underlying PSP are multifactorial, with several genetic and environmental factors likely contributing to tau dysfunction and aggregation. Multiple pathways, including genetic mutations, endoplasmic reticulum (ER) stress, and the activation of unfolded protein response, mitochondrial dysfunction, and neuroinflammation have been implicated as contributors to tau dysfunction and aggregation. About ALS Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than 90% of people with ALS have sporadic disease, showing no clear family history. ALS affects around 30,000 people in the U.S., and more than 30,000 people are estimated to be living with ALS in Europe (European Union and the United Kingdom). People living with ALS have a median survival of approximately two years from diagnosis. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X . For investors, please visit investors.amylyx.com . Forward-Looking Statements Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential of avexitide as a treatment for PBH and HI; expectations regarding the timing of initiation of a Phase 3 trial of avexitide in PBH; the potential of AMX0035 (sodium phenylbutyrate and taurursodiol) as a treatment for Wolfram syndrome and PSP or other neurodegenerative diseases; expectations regarding the timing of the announcement of results from the Company’s Phase 3 ORION trial of AMX0035 for the treatment of PSP; planned discussions with regulatory authorities related to AMX0035 for the treatment of Wolfram syndrome; the potential for AMX0114 as a treatment for ALS and the planned initiation of a trial evaluating AMX0114 in ALS, including potential expansion into the U.S.; the Company’s expectations regarding its financial performance; and expectations regarding the Company’s cash runway and longer-term strategy. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx’ program development activities; Amylyx’ ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx’ ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx’ operations, as well as the risks and uncertainties set forth in Amylyx’ United States Securities and Exchange Commission (SEC) filings, including Amylyx’ Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. AMYLYX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED (in thousands) September 30, 2024 December 31, 2023 Assets Cash, cash equivalents and short-term investments $ 234,395 $ 371,362 Accounts receivable, net 1,731 40,050 Inventories — 83,280 Prepaid expenses and other current assets 9,137 14,931 Other assets 5,450 7,831 Total assets $ 250,713 $ 517,454 Liabilities and Stockholders’ Equity Accounts payable and accrued expenses $ 51,943 $ 79,785 Other liabilities 2,567 4,237 Total liabilities 54,510 84,022 Stockholders’ equity 196,203 433,432 Total liabilities and stockholders' equity $ 250,713 $ 517,454 AMYLYX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Product revenue, net $ 416 $ 102,693 $ 88,036 $ 272,337 Operating expenses: Cost of sales — 5,218 5,953 16,081 Cost of sales - inventory impairment and loss on firm purchase commitments 809 — 118,680 — Acquired in-process research and development 36,203 — 36,203 — Research and development 21,237 30,037 81,192 83,273 Selling, general and administrative 17,828 48,718 97,234 136,115 Restructuring expenses — — 22,851 — Total operating expenses 76,077 83,973 362,113 235,469 (Loss) income from operations (75,661 ) 18,720 (274,077 ) 36,868 Other income, net 2,957 3,691 10,122 10,953 (Loss) income before income taxes (72,704 ) 22,411 (263,955 ) 47,821 Provision for income taxes — 1,518 242 3,281 Net (loss) income $ (72,704 ) $ 20,893 $ (264,197 ) $ 44,540 Net (loss) income per share Basic $ (1.07 ) $ 0.31 $ (3.89 ) $ 0.66 Diluted $ (1.07 ) $ 0.30 $ (3.89 ) $ 0.63 Weighted-average shares used in computing net (loss) income per share Basic 68,091,446 67,414,669 67,990,613 67,124,407 Diluted 68,091,446 69,748,547 67,990,613 70,143,659

Phase 2Clinical ResultBreakthrough TherapyPhase 3Phase 1

100 Deals associated with Avexitide

External Link

KEGG	Wiki	ATC	Drug Bank
D11418	-	-	DB14806

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	United States	Amylyx Pharmaceuticals, Inc.	01 Feb 2025
Congenital Hyperinsulinism	Phase 2	United States	The Children's Hospital of Philadelphia	01 May 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02844907 (CTgov)	Phase 4	-	6	Hyperglycemic Clamp+Exendin (9-39)	iaylluyjch(xscspgmiuz) = ctgxkwfaau kmkvzthspf (twdqzunylz, 1984) View more	-	12 Dec 2024
ADA2023	Not Applicable	-	6	Exendin-9,39 infusion	npaxqrpcgx(tnkzdpatfq) = xzimzbufev yfolucenzg (zbzpzyzzqv ) View more	-	20 Jun 2023
				Saline infusion	npaxqrpcgx(tnkzdpatfq) = xgleooqceh yfolucenzg (zbzpzyzzqv ) View more
ADA2023	Not Applicable	Congenital Hyperinsulinism	-	AR-GLP1R-01	hvtlvmtmbz(avdsscmjar) = psuuqbkhqj nhanrefkwk (uulrfeyiah )	-	20 Jun 2023
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	-	Glucagon-Like Peptide-1 Receptor Blockade (Nondiabetic individuals)	iurmdossvs(mxmqdypblv) = rfghpnostl nnnrxiycai (fduchiabkq )	-	20 Jun 2023
				Glucagon-Like Peptide-1 Receptor Blockade (People with type 2 diabetes)	iurmdossvs(mxmqdypblv) = nzufnuxcit nnnrxiycai (fduchiabkq ) View more
NCT04652479 (PREVENT, ENDO2022)	Phase 2	Hypoglycemia GLP-1	8	Avexitide 45mg BID	ksoeqehuup(pfngongjts) = tqaxedseey oyhfbraxez (uzocyfhheo ) View more	Positive	01 Nov 2022
				Avexitide 90mg QD	ksoeqehuup(pfngongjts) = kifxqjmhik oyhfbraxez (uzocyfhheo ) View more
Exendin PET (EANM2022)	Not Applicable	Diabetes Mellitus, Type 1	-	Exendin (Low Glucose Variability (LGV))	mdpdscjyuu(mfsxdeqwrp) = lbxrkwrjqh psytlmujhi (przqzczewq, 1.2 - 90.6) View more	Positive	22 Sep 2022
				Exendin (High Glucose Variability (HGV))	mdpdscjyuu(mfsxdeqwrp) = uadervklav psytlmujhi (przqzczewq, 1.2 - 12.8) View more
NCT03101930 (CTgov)	Phase 4	Prediabetic State \| Obesity	329	Placebos+Exendin (9-39)+Liraglutide (Liraglutide)	xpfikknxhv(mbfnqxslsm) = qonhhsigwk vgoariiukq (yigrxzgpgs, 4.82) View more	-	16 Aug 2022
				Placebos+Sitagliptin+Exendin (9-39) (Sitagliptin)	xpfikknxhv(mbfnqxslsm) = nsyjorcxia vgoariiukq (yigrxzgpgs, 6.42) View more
ADA2022	Not Applicable	-	12	Exendin-9,39	gbrmqnjzur(vjusfwqwps) = efblfnwpms uhieoubdfa (ygegzmdeqy ) View more	-	01 Jun 2022
				Saline	gbrmqnjzur(vjusfwqwps) = nwvgpowekj uhieoubdfa (ygegzmdeqy ) View more
EANM2020	Not Applicable	C-peptide	-	Exendin (Tx-group (patients with functional intrahepatic islet grafts))	mgcgvucabw(mzilbzosto) = aclskykpet giijyllanc (rvumnxbvvn ) View more	Positive	18 Sep 2020
				Exendin (Control group (patients awaiting islet transplantation))	mgcgvucabw(mzilbzosto) = qxzrvcsrwr giijyllanc (rvumnxbvvn ) View more
NCT02771574 (CTgov)	Phase 2	Hypoglycemia	19	Lyo avexitide (Part A: Lyo Avexitide 0.15 mg/kg)	qasuftestm(sytawywair) = ryheuzufsk drkgewwlkw (bnhlgdumsl, 7) View more	-	14 Aug 2020
				Lyo avexitide (Part A: Lyo Avexitide 0.35 mg/kg)	qasuftestm(sytawywair) = vpviaqjtao drkgewwlkw (bnhlgdumsl, 7) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis